ERBB2 and breast cancer: Notably, the limited efficacy of immune checkpoint inhibitors (ICIs) in HER2-positive BC is well documented [40], and our results highlight the importance of investigating qualitative differences in T cell populations within this subtype, which may provide new insights into its tumor biology.